Onyx Pharmaceuticals, Inc. (ONXX)
-NasdaqGS 89.98 
0.11(0.12%) Jun 17, 4:00PM EDT|After Hours
:
89.98 0.00 (0.00%) Jun 17, 5:06PM EDT
| Prev Close: | 90.09 |
|---|
| Open: | 90.64 |
|---|
| Bid: | 85.01 x 100 |
|---|
| Ask: | 91.99 x 100 |
|---|
| 1y Target Est: | 110.06 |
|---|
| Beta: | 1.69 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | 87.89 - 91.17 |
|---|
| 52wk Range: | 44.00 - 101.57 |
|---|
| Volume: | 848,936 |
|---|
| Avg Vol (3m): | 1,139,390 |
|---|
| Market Cap: | 6.54B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- The Top 5 Diseases Caused by Obesityat Motley Fool(Sun, Jun 16)
- Why ImmunoGen Is a Buy Right Now?at Motley Fool(Sat, Jun 15)
- Onyx Pharmaceuticals, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-12-2013 10:00 AMat Seeking Alpha(Wed, Jun 12)
- Drug Rejected! Let's Rejoice?at Motley Fool(Tue, Jun 11)
- DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lowerat TheStreet(Mon, Jun 10)
- Onyx Pharmaceuticals to Present at Upcoming Investor ConferencesMarketwired(Thu, Jun 6)
- Aveo's Future Depends on Triple-Negative Breast Cancerat TheStreet(Thu, Jun 6)
- Revlimid Gains, Celgene Losesat Motley Fool(Wed, Jun 5)
- Analysts: Lululemon Should Beat Estimates and 3 More Research Notes to Look Intoat Wall St. Cheat Sheet(Tue, Jun 4)
- Celgene at ASCO: Ho-Hum, Ho-Hum, and Hmmmat Motley Fool(Tue, Jun 4)
- Positive Data on Bayer/Onyx's NexavarZacks(Mon, Jun 3)
- Onyx Stock Falls On Unusually High Volume (ONXX)at TheStreet(Mon, Jun 3)
- Drug Stocks Get Shaken Up At Cancer Confabat Barrons.com(Mon, Jun 3)
- Two Diversified Biotechs to Watch After Impressive ASCO Dataat Motley Fool(Mon, Jun 3)
- [video] Pharma's Cancer Fight Makes Stridesat CNBC(Mon, Jun 3)
Key Statistics
| Forward P/E (1 yr): | 160.68 |
|---|
| P/S (ttm): | 15.04 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.73 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.44 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -1.17 |
|---|
Business Summary
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally.
View More